Align Technology (ALGN) loses appeal as 9th circuit revives monopoly suit and orders trial

A revived antitrust suit after appellate reversal follows a familiar sequence in this kind of litigation: the case returns to the district court for trial, discovery that had been paused resumes, and both sides re-price settlement versus verdict risk. Appellate orders reinstating claims rather than deciding them on the merits historically leave the liability question open, so the read-through at this stage is about duration and legal overhang rather than any established wrongdoing. For a monopoly claim against a dominant incumbent, the transmission channel to the equity is typically twofold: a higher litigation discount on the multiple while the case runs, and a tail scenario involving remedies or damages tied to the franchise's pricing power, which in this name's case sits at the core of its aligner business. The actors worth noting are the private plaintiffs pressing the claim, whose willingness to settle tends to firm up only after trial dates are set, and the company, whose prior form in contested IP and competition disputes has been to litigate rather than fold early. The follow-ons are procedural: the trial schedule, any summary judgment motions refilled on remand, and disclosure in coming filings of how the company frames the exposure. As an appellate ruling rather than a verdict, the signal is that the overhang lengthens, not that liability has been found.